Cargando…
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer
Osimertinib is the latest generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor used for patients with EGFR-mutated non-small cell lung cancer (NSCLC). We aimed to explore the novel mechanisms of osimertinib by particularly focusing on EGFR-independent effects, which have not...
Autores principales: | Nanamiya, Ren, Saito-Koyama, Ryoko, Miki, Yasuhiro, Inoue, Chihiro, Asavasupreechar, Teeranut, Abe, Jiro, Sato, Ikuro, Sasano, Hironobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395224/ https://www.ncbi.nlm.nih.gov/pubmed/34445227 http://dx.doi.org/10.3390/ijms22168522 |
Ejemplares similares
-
The correlation of p22(phox) and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma
por: Kobayashi, Masayuki, et al.
Publicado: (2019) -
11β hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma
por: Saito, Ryoko, et al.
Publicado: (2020) -
SUN-742 Roles of Progesterone Receptor Isoform B in Non-Small Cell Lung Cancer Tumor Progression
por: Asavasupreechar, Teeranut, et al.
Publicado: (2020) -
PD-L1 Induction by Cancer-Associated Fibroblast-Derived Factors in Lung Adenocarcinoma Cells
por: Inoue, Chihiro, et al.
Publicado: (2019) -
Low Expression of EphB2, EphB3, and EphB4 in Bladder Cancer: Novel Potential Indicators of Muscular Invasion
por: Lee, Tae Ho, et al.
Publicado: (2021)